Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Bio-Rad Laboratories Inc(BIO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BIO
11/09/2026: BIO (2-star) is currently NOT-A-BUY. Pass it for now.
Bio-Rad Laboratories is a global supplier of specialized life science research and clinical diagnostic equipment. The company maintains a leading position in niche areas like Droplet Digital PCR and clinical quality control, benefiting from high-margin, recurring revenue streams provided by its consumables. Its primary growth story revolves around the continued adoption of its advanced molecular technologies in both research and clinical labs. However, it faces risks from intense competition from larger industry peers and exposure to fluctuations in research funding. The company is best suited for growth-oriented investors who can look past short-term equity market volatility and focus on long-term technological development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers steady, long-term growth potential in life sciences, but lacks the high-octane growth profile of tech-focused firms. |
| Momentum investor | Weak fit | The stock often moves based on long-term fundamentals rather than short-term price momentum or hype. |
| Value investor | Mixed fit | Valuation can be attractive depending on the market cycle and the fluctuating value of the company's Sartorius stake. |
| Dividend investor | Weak fit | The company does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Mixed fit | While the business is stable, the stock can experience volatility due to its minority equity investment exposure. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The share price is sensitive to changes in the valuation of the company's equity holdings in other entities. |
| Valuation risk | Medium | Investors must account for both the operating business and the value of external investment assets. |
| Competition risk (Diversified Life Science) | High | Competition from firms like TMO and DHR creates persistent pressure on margins and R&D spend. |
| Business quality | Strong | The company has a long history of reliable, high-quality instrumentation and a deep base of recurring revenue. |
| Dividend income | Low / none | There is no dividend policy, meaning capital returns rely entirely on share price appreciation. |
| Execution risk | Medium | Successful integration of new technologies into the clinical diagnostic market is essential for growth. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -19.88% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/09/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.26B USD | Price to earnings Ratio 10.14 | 1Y Target Price 340 |
Price to earnings Ratio 10.14 | 1Y Target Price 340 | ||
Volume (30-day avg) 248.5K shares | Beta 1.06 | 52 Weeks Range 236.73 - 396.23 | Updated Date 11/08/2026 |
52 Weeks Range 236.73 - 396.23 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 37.64 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Life Science | Instruments and consumables for research, including ddPCR and protein purification products. | The company makes steady money by selling the tools that labs buy repeatedly for their research. |
| Clinical Diagnostics | Test kits, QC software, and hardware for hospitals and testing laboratories. | This is a reliable segment providing essential testing materials that hospitals require every day. |
| Equity Investments | Significant minority stake in Sartorius AG. | Bio-Rad's portfolio includes financial interests that can impact the company's total reported value. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When After Market | Estimate 2.61 | Actual 2.65 |
Profitability
Profit Margin 39.45% | Operating Margin (TTM) 11.82% |
Management Effectiveness
Return on Assets (TTM) 1.5% | Return on Equity (TTM) 14.27% |
Valuation
Trailing PE 10.14 | Forward PE 41.67 | Enterprise Value 9.95B | Price to Sales(TTM) 3.96 |
Enterprise Value 9.95B | Price to Sales(TTM) 3.96 | ||
Enterprise Value to Revenue 3.84 | Enterprise Value to EBITDA 6.48 | Shares Outstanding 21.83M | Shares Floating 21.47M |
Shares Outstanding 21.83M | Shares Floating 21.47M | ||
Percent Insiders 16.3 | Percent Institutions 89.84 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.